Menu Search
Equities

Talis Biomedical Corp

TLIS:PKC

Talis Biomedical Corp

Actions
  • Price (USD)1.85
  • Today's Change-0.05 / -2.63%
  • Shares traded12.92k
  • 1 Year change-68.64%
  • Beta1.6976
Data delayed at least 15 minutes, as of Sep 20 2024 20:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Talis Biomedical Corp had revenues fall -55.65% from 4.81m to 2.13m, though the company grew net income from a loss of 113.01m to a smaller loss of 62.01m.
Gross margin95.10%
Net profit margin-12,506.37%
Operating margin-13,510.29%
Return on assets-52.13%
Return on equity-70.48%
Return on investment-57.23%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Talis Biomedical Corp fell by 53.69m. Cash Flow from Financing totalled 33.00k or 1.55% of revenues. In addition the company used 53.24m for operations while cash used for investing totalled 486.00k.
Cash flow per share-27.59
Price/Cash flow per share--
Book value per share26.69
Tangible book value per share26.69
More ▼

Balance sheet in USDView more

Talis Biomedical Corp appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.76
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 46.40%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		41.53
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.